NIH: Study Will Identify Most Promising Therapies for COVID-19
The NIAID has launched a new study aimed at accelerating the most promising therapies in the fight against coronavirus disease 2019.
All articles by Steve Duffy
Pfizer, BioNTech Sign Deal for 100 Million COVID-19 Vaccine Doses
The US Department of Health and Human Services and the Department of Defense have agreed to receive 100 million doses of BNT162, a vaccine for SARS-CoV-2, once the manufacturers obtains approval or emergency use authorization (EUA) from the FDA
Haymarket Medical Network Joins Ad Council Private Marketplace
Haymarket Medical Network, a part of business media company Haymarket Media, Inc., is proud to join the Ad Council’s first ever Private Marketplace (PMP) along with other partners Cadreon, The Trade Desk and Acxiom.
FDA Approves OTC Combination of Ibuprofen and Acetaminophen for Minor Arthritis Pain
The FDA Advil Dual Action with Acetaminophen for the temporary relief of minor aches and pains due to arthritis and more.
Naproxen and Esomeprazole Magnesium Delayed-Release Tablets Now Available
Dr. Reddy’s Laboratories announced the launch of Naproxen and Esomeprazole Magnesium Delayed-Release Tablets, the generic equivalent to Vimovo®.
FDA Clears OTC Electromagnetic Pulse Therapy for Musculoskeletal Pain Relief
The over-the-counter (OTC), drug-free medical device, ActiPatch®, has obtained a new 510(k) clearance from the Food and Drug Administration (FDA) for the adjunctive treatment of musculoskeletal pain.
Haymarket Medical Education Receives Interprofessional Joint Accreditation for the Healthcare Team
Caroline O. Pardo, Ph.D., General Manager for Haymarket Medical Education, is pleased to announce that HME, based in Paramus, NJ, has been accredited as a provider of interprofessional continuing education by the Accreditation Council for Continuing Medical Education, the Accreditation Council for Pharmacy Education, and the American Nursing Credentialing Center.
New Treatment Approved for Osteoporosis With High Risk for Fracture
The Company is currently conducting a comparative study with the aim of having the treatment designated as a therapeutic equivalent to Forteo.
Sustained Response With Secukinumab in Axial Spondyloarthritis
Results showed that at Week 52, secukinumab was associated with a significant and clinically meaningful reduction in disease activity compared with placebo.
Rituximab Gains Expanded Approval in Pediatrics
Granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) are rare diseases that are generally specific to the lungs, kidneys and upper airways.
-
Loading...
-
Loading...
Next post in Vasculitis
